# Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

> **NCT04922008** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 356 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine and trastuzumab
- **DRUG:** vinorelbine and trastuzumab

## Key facts

- **NCT ID:** NCT04922008
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 356 (ESTIMATED)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922008, "Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04922008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*